Latest News for: mrd
Edit
Het Financieele Dagblad: ‘Forbion haalt €2,3 mrd op en wordt grootste Europese investeerder in biotech’ (Forbion Capital Partners Management Services BV)
Public Technologies 06 Oct 2026
Het Financieele Dagblad's article "Forbion haalt €2,3 mrd op en wordt grootste Europese investeerder in biotech" covers Forbion's largest fundraising to date ... Attachments Original document Permalink. Disclaimer ... (noodl. 134983350) .
Edit
In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98% (44/45) (Form 8-K) (Immix Biopharma Inc)
Public Technologies 29 Sep 2026
- In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98% (44/45) -.
Edit
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis (Immix Biopharma Inc)
Public Technologies 29 Sep 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 134785980) .
Edit
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Nasdaq Globe Newswire 25 Sep 2026
Biodesix-led tumor-informed and tumor-naïve programs ...
Edit
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition ...
Nasdaq Globe Newswire 25 Sep 2026
Edit
2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression
PR Newswire 25 Sep 2026
Edit
The Milton Standard Journal
19 Sep 2026
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
Edit
Adaptive Biotechnologies Announces Update to NCCN Guidelines� for Multiple Myeloma, Strengthening MRD Testing Recommendations and ...
Nasdaq Globe Newswire 17 Sep 2026
Edit
Burning Rock's Second WES-Based Personalized MRD Kit Enters NMPA Special Review Procedure for Innovative Medical Devices (Burning Rock Biotech Ltd)
Public Technologies 09 Sep 2026
Edit
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma ...
Business Wire 14 Jul 2026- 1